Long Term Trends in Chronic Hepatitis B Virus Infection Associated Liver Transplantation Outcomes in the United States.

Young K, Liu B, Bhuket T et al.

Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA.

Journal of viral hepatitis. Mar 2017.

With effective antiviral therapies, rates of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and decompensated liver disease requiring liver transplantation (LT) are expected to decrease. We aim to evaluate overall trends in LT waitlist registrations, waitlist survival, and likelihood of receiving LT among chronic HBV patients in the U.S. Using the United Network for Organ Sharing database, we retrospectively evaluated adults (age >18) with chronic HBV (with and without HCC) listed for LT from 1992-1996 (Era 1) vs. 1997-2004 (Era 2) vs. 2005-2015 (Era 3). Multivariate Cox-regression models evaluated probability of waitlist survival and receiving LT. Overall, 6797 chronic HBV adults were listed for LT. While the total number of HBV patients listed for LT remained stable, the proportion of HBV patients with HCC increased from 5.4% in Era 1 to 39.0% in Era 3. Compared to Era 1, waitlist mortality was higher in Era 2 (HR 4.55, p<0.001) and Era 3 (HR 3.63, p<0.001). However, in the most recent era, waitlist mortality significantly improved (compared to 2005-2007: 2008-2011: HR 0.74, p = 0.05, 95%CI 0.55-0.99; 2012-2015: HR 0.53, p<0.001, 95%CI 0.38-0.75). Probability of receiving LT was also lower with latter time periods (compared to 2005-2007: 2008-2011: HR 0.77, p <0.001 95%CI 0.68-0.86; 2012-2015: HR 0.61, p <0.001, 95%CI 0.54-0.69). Although the number of HBV patients requiring LT remained stable, the proportion of HBV patients with HCC continues to rise. The decrease in waitlist mortality and lower likelihood of LT among HBV patients may reflect the effectiveness of antiviral therapies in delaying disease progression in the current era. This article is protected by copyright. All rights reserved. Pubmed